關於 cookie 的說明

本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗,我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示,便表示您已接受我們的網站使用條款。

搜尋結果Search Result

符合「Trade show news」新聞搜尋結果, 共 3245 篇 ,以下為 121 - 144 篇 訂閱此列表,掌握最新動態
Antengene Presents Four Preclinical Posters at AACR 2024

SHANGHAI and HONG KONG, April 6, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced the presentation of four preclinical posters at the 2024 American Association for Cancer Research Annual Meeting (AACR 2024), taking place from April 5th to April 10th at the San Diego Convention Center in San Diego, California, the United States. The posters showcased four of Antengene's high-potential emerging programs, including ATG-042, tracking to a H1 2025 IND filing; ATG-022, in Phase II dose expansion studies in China and Australia; AnTenGagerTM platform, Antengene's proprietary T-cell engager (TCE) platform; and ATG-102, which could be the first IND candidate from AnTenGagerTM platform. ATG-042, an oral small molecule MTAPnull-selective PRMT5 inhibitor holding the promise as a best-in-class drug. Study results showed that ATG-042 has the potential to elegantly target tumor cells while sparing healthy cells, with an attractive developability profile. ATG-022 is an Claudin 18.2 antibody-drug conjugate. The detailed updated data of the Claudin 18.2 (CLDN18.2) companion diagnostic antibody candidate for ATG-022 showed that the antibody has higher sensitivity compared to commercially available kits. AnTenGagerTM, Antengene's proprietary TCE platform with the ability to induce target-dependent T-cell activation, has potent anti-tumor effects and lower risk of cytokine release syndrome (CRS). ATG-102, a LILRB4 x CD3 TCE, is being developed for the treatment of acute myeloid leukemia (AML). Details of the posters: ATG-042 (MTAPnull-selective PRMT5 Inhibitor) Title: Preclinical characterization of ATG-042, a novel MTAPnull-selective PRMT5 inhibitor Abstract: 4592  Session Category: Experimental and Molecular Therapeutics Session Title: HDAC and Methyltransferase Inhibitors Date: April 9, 2024 Time: 9:00 AM - 12:30 PM (Pacific Time)           12:00 AM - 3:30 AM, April 10, 2024 (Beijing Time) Location: Poster Section 24 This preclinical study was designed to test the in vitro/in vivo efficacy, and preclinical pharmacokinetic (PK) properties of ATG-042. According to the results, ATG-042 demonstrated a potent and selective inhibitory effect on the proliferation of MTAP knockout cells, showed high permeability, good metabolic stability, a low risk of drug-drug interaction (DDI), and high oral bioavailability. Importantly, ATG-042 demonstrated good brain penetrability. In CDX models, ATG-042 also potently and selectively inhibited tumor growth without inducing weight loss. These data suggest that ATG-042 is an orally administered, MTAPnull-selective PRMT5 inhibitor with potent efficacy against MTAP-null tumors, as well as demonstrating good tolerability and favorable preclinical PK profiles. Companion Diagnostic Antibody for ATG-022 (Claudin 18.2 ADC) Title: Development of a novel companion diagnostic immunohistochemistry antibody for Claudin 18.2-targeted therapies Abstract: 1032 Session Category: Clinical Research Session Title: Diagnostic Biomarkers 1 Date: April 7, 2024 Time: 1:30 PM - 5:00 PM (Pacific Time)            4:30 AM - 8:00 AM, April 8, 2024 (Beijing Time) Location: Poster Section 42 Despite the substantial correlation between the expression of CLDN18.2 and the efficacy of therapies targeting CLDN18.2, no companion diagnostic (CDx) antibodies specific to CLDN18.2 have been approved to date. This poster presents the discovery and validation of a novel, highly sensitive immunohistochemistry (IHC) antibody that selectively identifies CLDN18.2. According these data, the monoclonal antibody (mAb) clone 43F11 showed positive cell surface IHC staining on CLDN18.2-expressing cells following fixation but demonstrated no staining on CLDN18.1-expressing cells. Moreover, the 43F11 antibody accurately identified the expression level of CLDN18.2 in an IHC assay, utilizing tumor tissues and patient-derived xenograft (PDX) samples with predetermined expression levels of CLDN18.2. When compared to the commercially available IHC antibody EPR19202, the 43F11 antibody demonstrated greater sensitivity, enabling positive staining on cancer tissues with significantly lower expression levels of CLDN18.2. These data suggest that the 43F11 antibody possesses superior sensitivity compared to the benchmark antibody and has the potential to serve as an effective patient stratification tool. AnTenGagerTM Platform Title: AnTenGagerTM, a novel "2+1" T cell engager platform, enables conditional T cell activation with reduced risk of CRS Abstract: 6343 Session Category: Clinical Research Session Title: Antibodies 2 Date: April 9, 2024 Time: 1:30 PM - 5:00 PM (Pacific Time)            4:30 AM - 8:00 AM, April 10, 2024 (Beijing Time) Location: Poster Section 41 This poster presents an in-depth overview of the design and mechanism of action for the proprietary AnTenGagerTM T cell engager (TCE) platform. These TCEs are specifically designed to produce an anti-cancer effect with a lower risk of systemic CD3 activation and cytokine release syndrome (CRS), potentially paving the way for use in solid tumors. AnTenGagers TCE constructs are designed to induce cytotoxicity by forming a T cell receptor (TCR)-independent immune synapse. AnTenGagers do this by simultaneously binding tumor associated antigens (TAAs) on cancer cells and specific conformational epitopes on CD3+ T-cells. Presented data show that AnTenGagers are able to effectively bind to specific CD3 confirmational epitopes and demonstrate higher cytotoxicity compared to benchmark compounds. AnTenGagers are compatible with a range of TAAs, and that AnTenGagers have improved cytotoxicity compared to benchmark compounds, as demonstrated in cellular assays and a murine myeloma model. Data from the murine models also showed that AnTenGagers resulted in significantly lower concentrations of pro-inflammatory cytokines, further supporting a lower risk of CRS. AnTenGagers also have good "developability" properties based on good stability under stress conditions. Together, these data support the potential for AnTenGagers to be used in solid tumors, based on their ability to simultaneously bind TAAs and specific CD3+ confirmational epitopes, resulting in higher TAA-dependent cytotoxicity compared to benchmarks and the reduced risk of CRS, opening the door to a broad new class of cancer therapies. ATG-102 (LILRB4 x CD3 T Cell Engager) Title: ATG-102, a novel LILRB4 x CD3 T cell engager, targeting two non-overlapping epitopes of LILRB4, for the treatment of monocytic AML Abstract: 2372 Session Category: Clinical Research Session Title: Antibodies 1 Date: April 8, 2024 Time: 9:00 AM - 12:30 PM (Pacific Time)           12:00 AM - 3:30 AM, April 9, 2024 (Beijing Time) Location: Poster Section 38 The use of TCEs to treat AML (acute myeloid leukemia) has been limited the difficulty in identifying specific antigens that are expressed on AML and leukemic stem cells but not normal hematopoietic stem cells. The preferential expression of LILRB4 on M4/M5 subtype acute myeloid leukemia (AML) cells renders it a highly attractive target for the treatment of AML. These data show that an AnTenGagerTM based TCE, which binds to two distinct epitopes of the LILRB4 receptor, can induce potent T-cell dependent cellular cytotoxicity (TDCC) to produce potent anti-tumor efficacy in vitro and in vivo. The poster outlines the design and structural characteristics of ATG-102 comprised of two LILRB4 epitopes and an anti-CD3 single chain fragment variable (scFv) inserted in the hinge region on one of the LILRB4 heavy chains. Characterization data include: -Binding epitope and affinity studies showing that ATG-102 binds to the target TAA epitopes as well as conformational CD3 epitopes. -T cell binding and T-cell dependent cytotoxicity assays show that compared to the benchmark, ATG-102 demonstrated less non-specific T cell binding or activation, whilst inducing more potent TDCC against LILRB4+cells and enhanced in vivo anti-AML efficacy. These data highlight the structural characteristics of ATG-102 and demonstrate potent in vitro and in vivo anti-tumor efficacy which support further clinical evaluation of ATG-102. About Antengene Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders". Since 2017, Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 29 investigational new drug (IND) approvals in the U.S. and Asia, and submitted 11 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO® (selinexor) already approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore and Australia. Forward-looking statements The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2023, and the documents subsequently submitted to the Hong Kong Stock Exchange. Investor Contacts: Donald LungE-mail: Donald.Lung@antengene.com  Mobile: +86 18420672158 PR Contacts:Peter QianE-mail: Peter.Qian@antengene.com Mobile: +86 13062747000

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 1053 加入收藏 :

PARIS, April 6, 2024 /PRNewswire/ -- At the Gamers Assembly in Poitiers, France, Optic 2000 & AUSTRALIEGAD set the best video game players an ambitious challenge: to take on a blind player, equipped with an innovative device, in one of the most legendary games. It was an inspiring experience, designed to change the way people look at visual impairment.     Video from BRUT Media   "OPTIC 2000 CHALLENGER" Optic 2000 is committed to supporting the development of technological innovation to help visually impaired people live independently. Since 2023 the company has been supporting the start-up Artha and its mobility aid for the visually impaired: a belt that transforms images into impulses. https://www.instagram.com/p/C5B8SoFN3oW/?hl=fr This weekend, Optic 2000 and Artha launched the "Optic 2000 Challenger" challenge with Salim Ejnaïni, the first visually impaired player equipped with an Artha belt, taking on able-bodied players on the famous Trackmania game.  This partnership reflects Optic 2000's commitment to low vision and its desire to innovate on a daily basis to support and promote the independence of visually impaired people. "As well as being proud to be behind this major first, it's a great opportunity to help change the way people view visual impairment. Our mission is to support our customers throughout their lives, to provide them with the best possible visual comfort." Benoit Jaubert, Managing Director of Groupement Optic 2000. A stand dedicated to raising public awareness This major event was also an opportunity to raise public awareness of visual impairment and the risks of overexposure to screens. On the Optic 2000 stand, visitors could find out more about how to protect their eyesight and opticians were available on site to carry out eye tests. The public could also enjoy an inclusive experience with a workshop designed to raise awareness of visual impairment: by wearing special glasses simulating visual problems (macular degeneration, glaucoma, etc.), visitors could slip into the shoes of a visually impaired person whilst playing a game to raise awareness and understanding of this handicap. Throughout the weekend, AUSTRALIEGAD's cameras followed Salim behind the scenes at the Optic 2000 Challenger, from preparation to the tournament itself. The video will be available next week on the OPTIC 2000 networks. Media Contact: jallain@australiegad.com       

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 1333 加入收藏 :
Rainbow Robotics unveils RB-Y1, Korea's first bimanual mobile manipulator

- In March, "2024 Smart Factory Automation Industry Exhibition (SF+AW 2024)" was first released to the public - Posting various performance videos of bimanual mobile manipulator in the form of humanoids on YouTube channels DAEJEON, South Korea, April 5, 2024 /PRNewswire/ -- Rainbow Robotics, the robot platform company, announced that it has released detailed specifications of RB-Y1, the first bimanual mobile manipulator developed in Korea, and posted various performance videos on the Rainbow Robotics YouTube channel. Korea's first bimanual mobile manipulator RB-Y1 spec RB-Y1 is a form of mounting a humanoid-type double-arm robot on a wheel-type high-speed mobile base to enable work in various environments. In order to naturally perform various and complex tasks, both arms are equipped with 7 degrees of freedom and consist of a single leg with a 6-axis degree of freedom that can move the body. In particular, it is possible to move more than 50 cm vertically, making it possible to perform tasks at various heights. The driving operation speed is 2.5m/s, and various types of high-speed turning and sudden acceleration are possible using 20-axis full-body control. In addition, the center of gravity can be safely controlled by using a single leg with 6 degrees of freedom while driving. RB-Y1 has the level of reliability and performance of industrial robots because it was developed using the core components used in cooperative robots and AMR. Since it has 22 axes excluding wheels, it is complex to generate motion for this robot. However, it is possible to teach the robot (slave) by linking the data arm (master) to train them. It also has a function to prevent self-collision when the user teaches by setting the self-collision area of both arms. Additionally, a simulation environment for learning has been established to utilize AI. An official from Rainbow Robotics said, "These days, when Generative AI such as ChatGPT and Figure is a hot topic in the robot industry, we have developed a bimanual mobile manipulator in line with the AI era," adding, "We hope that the platform will overcome the limitations of existing industrial robots and be used in many industrial sites." Reference) RB-Y1 YouTube video linkDynamic driving - https://youtu.be/Y3538CJb6TY?si=ThIsr4TAWfRWSq3FPouring water - https://youtu.be/JX8_Z64zo_k?si=PcCGLF3q28KA_IX5Cup stacking - https://youtu.be/MMAiJi-kodg?si=_sKC8V8hMo3WehQS

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 498 加入收藏 :
Tracy King to Deliver Keynote Address at Cadmium Spark 2024

The Chief Learning Strategist and CEO of InspirEd will speak on how to drive success in the education space at Cadmium's annual conference FOREST HILL, Md., April 5, 2024 /PRNewswire/ -- Cadmium has confirmed that Tracy King, MA, CAE, Chief Learning Strategist & CEO of InspirEd will deliver the keynote address at their annual conference, Cadmium Spark. The address is scheduled for Tuesday, July 23rd, at Walter E. Washington Convention Center in Washington, D.C. King brings over 20 years of expertise in workforce development consulting, specializing in education strategy and learning design. Featured on NBC, Forbes, U.S. News, and more, King's unique approach centers on the intersection of learning science and technology, making them a thought leader and master learning designer in the field. "We are thrilled to have Tracy King deliver a Keynote address at Cadmium Spark," says Vicky Thompson, Chief Revenue Officer at Cadmium. "King brings a wealth of expertise and insights into education strategy, learning design, and workforce development that our attendees can greatly benefit from." Tracy King will also be hosting office hours and a workshop at Cadmium Spark, providing attendees with the opportunity to engage, ask questions, and gain personalized insights. Titled "Strategies for Profitable and Sustainable Education Programs," King's accelerated workshop will dive into key topics such as curriculum development, pricing strategies, marketing tactics, and operational efficiency. Cadmium Spark will mark the company's third biennial conference for professionals and decision-makers passionate about transforming the landscape of event technology and continuing education. The conference will provide keynote sessions, workshops, panel discussions, case studies, networking opportunities, and more. About Cadmium Cadmium empowers associations to harness the power of learning experiences by providing an integrated suite of solutions that streamline event management and continuing education. We understand that learning is about transformative moments, and we're here to help associations share those moments, create community, and drive meaningful change. For more information, visit https://gocadmium.com.  Contact:Jessie Reyes | CadmiumJessie.reyes@gocadmium.com  

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 472 加入收藏 :
Huahui Health to Present Preclinical Data of HH018-sesutecan at the 2024 AACR Annual Meeting

BEIJING, April 4, 2024 /PRNewswire/ -- Huahui Health Ltd.("Huahui Health"), a clinical stage biotechnology company focused on discovering and developing virology, hepatology, and oncology therapies, announced that it will present the results of preclinical data of HH018-sesutecan, a tumor microenvironment targeting CD98-directed ADC, at the American Association for Cancer Research (AACR) Annual Meeting 2024. The AACR meeting will be held April 5–10, 2024, in San Diego, California. Topic: A tumor microenvironment-targeting CD98-directed ADC confers robust anti-tumor activity in multiple cancers with favorable pharmacokinetics and safety profiles in preclinical models Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 4Session Date and Time: Wednesday Apr 10, 2024 9:00 AM - 12:30 PMLocation: Poster Section 54Poster Board Number: 1Abstract Presentation Number: LB425Presenter: Bin Chen, CEO of Huahui Health. Zhu Chen, CSO of ProfoundBio About Huahui Health Huahui Health is a clinical-stage biotechnology company founded in 2015 in Beijing, China. With a focus on virology, hepatology, and oncology, the company is dedicated to drug discovery, development, and antibody engineering. It has expanded its pipeline to include promising drug candidates in virology and oncology, aiming to launch multiple groundbreaking products and lead the way in antiviral and oncology research. Two leading programs have entered the pivotal clinical trial stage. One is HH-003, the first anti-preS1 HBV/HDV neutralizing antibody to enter a pivotal study for chronic HDV infection. The other is HH-120, an IgM-like ACE2-Fc recombinant fusion protein via nasal spray, currently undergoing a phase 3 trial for post-exposure prophylaxis of SARS-CoV-2. For more information, please visit www.huahuihealth.com.

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 416 加入收藏 :
Bybit Lights Up Dubai with Exclusive Events, Heavyweight Panels at Blockchain Life and Token2049: Shaping the Future of Blockchain

DUBAI, UAE, April 4, 2024 /PRNewswire/ -- Bybit, one of the world's top three crypto exchanges by volume, today announced the participation of its leadership team at the Blockchain Life 2024, Token2049, and special networking events in Dubai. This industry gathering presents a dynamic platform for Bybit to showcase its unwavering commitment to innovation, collaboration, and the responsible social advancement of blockchain technology. Bybit's leadership team will actively engage in thought-provoking panel discussions, covering a wide range of groundbreaking topics including the evolving role of crypto exchanges, the transformative power of blockchain for social good, and other exciting topics. Here's a snapshot of the Bybit team's agenda: Shaping the Evolving Role of Crypto Exchanges: Bybit CEO Ben Zhou will engage in a dynamic dialogue on the role of cryptocurrency exchanges in derivative market development on April 15th. Driving Social Impact: Bybit COO Helen Liu to introduce the new Blockchain for Good Alliance(BGA): Supporting projects that are making a positive impact and fueling the dreams of changemakers. Fostering Innovation: The Bybit x ICP Hack to Future with Head of Financial Products Hao Yang on April 16th. Discussing the innovative projects shaping the ICP ecosystem in the region, and rubbing shoulders with investors, partners, and influencers. Building Strong Collaborations: Bybit will host a series of networking events from April 15th to 20th, including the Bybit VIP Gala for MENA Networking Event and the Bybit x DMCC Web3 night in Dubai, fostering collaboration and driving the industry forward. Connecting with the Community: Bybit representatives will be readily available at Token2049 Dubai on April 18th, showcasing Bybit's cutting-edge products and engaging with attendees. Charting the Course for Mass Adoption: Exclusive sessions on Web3 security and mass adoption, alongside a luxurious VIP Gala Dubai on April 19th and 20th, set the stage for the widespread adoption of blockchain technology. "Bybit is here to empower users, connect the industry, and lead the way in this transformative journey," said Ben Zhou, Co-founder and CEO of Bybit. "We're excited to be at the forefront of these discussions in Dubai's robust blockchain environment, and we invite everyone to join us as we navigate this exciting future together." #Bybit / #TheCryptoArk / #BybitWeb3 / #keytoWeb3 About Bybit Bybit is one of the world's top three cryptocurrency exchanges by trading volume with 25 million users. Established in 2018, it offers a professional platform where crypto investors and traders can find an ultra-fast matching engine, 24/7 customer service, and multilingual community support. Bybit is a proud partner of Formula One's reigning Constructors' and Drivers' champions: the Oracle Red Bull Racing team. For more details about Bybit, please visit Bybit Press.For media inquiries, please contact: media@bybit.comFor more information, please visit: https://www.bybit.comFor updates, please follow: Bybit's Communities and Social Media Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 171 加入收藏 :
首 頁 我的收藏 搜 尋 新聞發佈